Boehringer Ingelheim
R. Paul Fracasso is a Senior Scientist at Boehringer-Ingelheim Pharmaceuticals, Inc. since March 2012, specializing in biomarker discovery, assay development, compound screening, and target validation for cardiometabolic disease drug projects. Prior to this role, R. Paul Fracasso served as a consultant in the Department of Virology at Bristol-Myers Squibb and as a Senior Scientist/Manager at Pfizer, focusing on molecular medicine and human genetics. R. Paul Fracasso's earlier experience includes positions as a Senior Investigator I at Bayer, where leadership in cancer research was demonstrated, and as a Research Scientist at Miles Pharmaceuticals, investigating Alzheimer's disease. Educationally, R. Paul Fracasso holds a Master's degree in Biological Sciences from Southern Connecticut State University, along with a Bachelor's degree in Biology and another in Philosophy/Psychology from the University of Connecticut, complemented by graduate coursework at Wesleyan University.
This person is not in any teams
This person is not in any offices
Boehringer Ingelheim
116 followers
At Boehringer Ingelheim they create value through innovation with one clear goal: to improve the lives of patients. They develop breakthrough therapies and innovative healthcare solutions in areas of unmet medical need for both humans and animals. As a family owned company, they focus on long-term performance. They are powered by 50.000 employees globally who nurture a diverse, collaborative and inclusive culture. Learning and development for all employees is key, because your growth is their growth.